arrow
P

Patrick Oeckl

ulm university hospital
H指数:41
被引数:6,991

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Convergence of Cerebrospinal Fluid Neuronal Biomarker Burden and MRI Lesion Pattern and Its Association With Short‐Term Outcome in Neuroinfectious Diseases

脑脊液神经元生物标志物负荷与<scp>MRI</scp>病灶模式的收敛及其与神经感染性疾病短期预后的关联

2026-11-020
OAAI
Plasma β‐synuclein associates with hippocampal synaptic density measured with [ 11 C]UCB‐J PET and plasma tau markers in Alzheimer's disease

血浆β-突触核蛋白与海马体突触密度(通过[ <sup>11</sup> C]UCB‐J PET测量)及血浆tau标志物在阿尔茨海默病中的关联

2026-10-270
OA
Tau isoform mapping across tissues and biofluids reveals a signature distinguishing Alzheimer’s disease from amyotrophic lateral sclerosis

tau异构体在组织与生物流体中的分布图谱揭示了区分阿尔茨海默病与肌萎缩侧索硬化症的标志物

2026-10-220
OAAI
Serum β-synuclein predicts dementia conversion and mortality beyond amyloid-β and phospho-tau

血清β-突触蛋白预测阿尔茨海默病转化和死亡率,其预测能力优于淀粉样蛋白-β和磷酸化tau蛋白

Brain
IF11.7
2026-10-210
PRE
Blood SOD1 Activity in ALS Patients Receiving Tofersen Treatment

ALS患者接受Tofersen治疗后的血液SOD1活性

2026-09-240
OAAI
Changes in serum β-synuclein precede blood biomarkers of Alzheimer pathology in Down syndrome

血清β-突触蛋白的变化先于唐氏综合征中阿尔茨海默病病理学的血液生物标志物

2026-09-230
OAAI
Targeted Proteomics upon Treatment with Tofersen Identifies Novel Response Markers for Superoxide Dismutase 1-Linked Amyotrophic Lateral Sclerosis

靶向蛋白质组学在Tofersen治疗中发现与超氧化物歧化酶1相关的肌萎缩侧索硬化症的新型应答标志物

2025-08-090
OAAI
Early increase of the synaptic blood marker β-synuclein in asymptomatic autosomal dominant Alzheimer's disease

无症状常染色体显性遗传性阿尔茨海默病患者中突触血标志物β-突触核蛋白的早期增加

2025-04-100
OAAI